160 related articles for article (PubMed ID: 37570067)
1. Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.
Elzayat EM; Sherif AY; Nasr FA; Attwa MW; Alshora DH; Ahmad SF; Alqahtani AS
Materials (Basel); 2023 Jul; 16(15):. PubMed ID: 37570067
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.
Sherif AY; Harisa GI; Shahba AA; Alanazi FK; Qamar W
Molecules; 2023 Jan; 28(1):. PubMed ID: 36615641
[TBL] [Abstract][Full Text] [Related]
3. Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.
Sherif AY; Harisa GI; Alanazi FK; Nasr FA; Alqahtani AS
AAPS PharmSciTech; 2022 Jul; 23(6):183. PubMed ID: 35773422
[TBL] [Abstract][Full Text] [Related]
4. TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies.
Harisa GI; Sherif AY; Alanazi FK; Ali EA; Omran GA; Nasr FA; Attia SM; Alqahtani AS
Colloids Surf B Biointerfaces; 2023 Mar; 223():113148. PubMed ID: 36706479
[TBL] [Abstract][Full Text] [Related]
5. Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach.
Sherif AY; Harisa GI; Shahba AA; Nasr FA; Taha EI; Alqahtani AS
Drug Dev Res; 2023 Nov; 84(7):1453-1467. PubMed ID: 37519092
[TBL] [Abstract][Full Text] [Related]
6. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.
Sherif AY; Harisa GI; Alanazi FK; Nasr FA; Alqahtani AS
Int J Nanomedicine; 2022; 17():3287-3311. PubMed ID: 35924261
[TBL] [Abstract][Full Text] [Related]
7. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.
Han Y; Zhang Y; Li D; Chen Y; Sun J; Kong F
Int J Nanomedicine; 2014; 9():4107-16. PubMed ID: 25187713
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
Ni XL; Chen LX; Zhang H; Yang B; Xu S; Wu M; Liu J; Yang LL; Chen Y; Fu SZ; Wu JB
Drug Deliv; 2017 Nov; 24(1):1501-1512. PubMed ID: 28961023
[TBL] [Abstract][Full Text] [Related]
9. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment.
Huang R; Li J; Kebebe D; Wu Y; Zhang B; Liu Z
Drug Deliv; 2018 Nov; 25(1):757-765. PubMed ID: 29528244
[TBL] [Abstract][Full Text] [Related]
10. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells.
Costa CP; Cunha S; Moreira JN; Silva R; Gil-Martins E; Silva V; Azevedo L; Peixoto AF; Sousa Lobo JM; Silva AC
Int J Pharm; 2021 Sep; 607():120933. PubMed ID: 34324988
[TBL] [Abstract][Full Text] [Related]
11. Hospital wastewater treatment using eco-friendly eugenol nanostructured lipid carriers: Formulation, optimization, and in vitro study for antibacterial and antioxidant properties.
Shajari M; Ahmadi N; Zamani M; Rostamizadeh K; Shapouri R
Water Environ Res; 2022 Jul; 94(7):e10751. PubMed ID: 35765847
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.
Kumar P; Mangla B; Javed S; Ahsan W; Aggarwal G
Nanomedicine (Lond); 2023 Aug; 18(18):1139-1160. PubMed ID: 37665053
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Kim CH; Sa CK; Goh MS; Lee ES; Kang TH; Yoon HY; Battogtokh G; Ko YT; Choi YW
Int J Nanomedicine; 2018; 13():6661-6675. PubMed ID: 30425481
[TBL] [Abstract][Full Text] [Related]
14. Mannose-Functionalized Isoniazid-Loaded Nanostructured Lipid Carriers for Pulmonary Delivery: In Vitro Prospects and In Vivo Therapeutic Efficacy Assessment.
Ahalwat S; Bhatt DC; Rohilla S; Jogpal V; Sharma K; Virmani T; Kumar G; Alhalmi A; Alqahtani AS; Noman OM; Almoiliqy M
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631023
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol: Isolation, and Its Nanostructured Lipid Carriers, Inhibits Cell Proliferation, Induces Cell Apoptosis in Certain Human Cell Lines Carcinoma and Exerts Protective Effect Against Paraquat-Induced Hepatotoxicity.
Elgizawy HA; Ali AA; Hussein MA
J Med Food; 2021 Jan; 24(1):89-100. PubMed ID: 32580673
[TBL] [Abstract][Full Text] [Related]
17. In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers.
Rashidzadeh H; Salimi M; Sadighian S; Rostamizadeh K; Ramazani A
Curr Drug Deliv; 2019; 16(10):923-930. PubMed ID: 31663477
[TBL] [Abstract][Full Text] [Related]
18. Bupivacaine (S75:R25) Loaded in Nanostructured Lipid Carriers: Factorial Design, HPLC Quantification Method and Physicochemical Stability Study.
Da Silva GHR; de Morais Ribeiro LN; Guilherme VA; de Castro SR; Breitkreitz MC; de Paula E
Curr Drug Deliv; 2018; 15(3):388-396. PubMed ID: 28745230
[TBL] [Abstract][Full Text] [Related]
19. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer.
Kebebe D; Wu Y; Zhang B; Yang J; Liu Y; Li X; Ma Z; Lu P; Liu Z; Li J
Int J Nanomedicine; 2019; 14():6179-6195. PubMed ID: 31447559
[No Abstract] [Full Text] [Related]
20. Preparation and Characterization of Undecylenoyl Phenylalanine Loaded-Nanostructure Lipid Carriers (NLCs) as a New α-MSH Antagonist and Antityrosinase Agent.
Vaziri MS; Tayarani-Najaran Z; Kabiri H; Nasirizadeh S; Golmohammadzadeh S; Kamali H
Adv Pharm Bull; 2023 Mar; 13(2):290-300. PubMed ID: 37342381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
